rf-fullcolor.png

 

November 25, 2024
by Jason Scott

Recon: Trump picks Makary to head FDA; FDA approves BridgeBio’s Attruby for rare heart condition

Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing.

In Focus: US
  • Trump's FDA pick is surgeon and writer Martin Makary (Reuters) (STAT) (Axios) (Politico) (Endpoints) (NYTimes) (ABC News)
  • What to make of Trump’s health care nominees (STAT)
  • Trump’s pick to run FDA is top exec of company that provides compounded weight-loss drugs (STAT)
  • Trump’s FDA director pick has a history of criticizing the agency. Here are seven examples (STAT)
  • ‘We dodged a bullet’: Biotech and pharma react to selection of Marty Makary for FDA commissioner (STAT)
  • Hims & Hers Shares Jump as Trump’s FDA Pick Seen as Major Ally (Bloomberg)
  • Merck halts Phase 3 trial with PAH drug Winrevair following positive interim data (Endpoints) (Reuters)
  • Thousands turn to Wegovy copies each month as FDA considers shortage status (Reuters)
  • US FDA approves BridgeBio's drug for rare heart condition (Reuters)
In Focus: International                                                                                                       
  • Japan Prices Kisunla Above Leqembi But May Cut In Future (Pink Sheet)
  • European Commission Needs More Manpower To Drive Medtech Change (MedTech Insight)
  • AZ's Truqap delivers phase 3 win in prostate cancer subtype after recent breast cancer miss (Fierce Pharma)
  • EU CHMP Opinions And MAA Updates (Pink Sheet)
Pharma & Biotech
  • Incyte touts Monjuvi data from Phase 3 follicular lymphoma trial as it heads to FDA (Endpoints)
  • Cassava shares plunge as controversial Alzheimer’s drug fails Phase 3 trial (Endpoints) (Reuters)
  • Gilead buys experimental HIV vaccines from a small Barcelona biotech (Endpoints)
  • Biohaven's spinal muscular atrophy drug fails to meet study goal (Reuters) (Endpoints)
  • Replimune aims to raise $125M; Otsuka makes another deal with Ionis (Endpoints)
  • Pfizer led industrywide sales surge in Q3 after several quarters of dominance by Eli Lilly, Novo Nordisk (Fierce Pharma)
Medtech
  • Musk's Neuralink to launch feasibility trial with brain implant, robotic arm (Reuters)
  • Boston Scientific to buy Intera Oncology, maker of liver cancer treatment (MedTech Dive)
  • Medtronic, Tempus testing AI to find potential TAVR patients (MedTech Dive)
  • Medtronic buys surgical instrument developer Fortimedix (MedTech Dive)
  • FDA plan would alert public sooner on high-risk device recalls (MedTech Dive)
  • Medtronic nets FDA nod for smart insulin pen app (MedTech Dive)
  • Generative AI Devices The Focus Of First FDA Digital Health Advisory Committee Meeting (MedTech Insight)
Government, Regulatory & Legal
  • It’s a Three-Peat: DEA and HHS Extend Telemedicine Flexibilities Until December 31, 2025 (FDA Law Blog)
  • Prognosis: Under Trump, the CDC is in big trouble, but the FDA might be OK (STAT)
  • US Supreme Court rejects tobacco firms' appeal over graphic warnings (Reuters)
  • Califf: Sponsors Should Go Beyond Letter Of Law With Trial Diversity Plans (Pink Sheet)
  • Proposed Bill Would Grow Medicare Coverage For Breakthrough Devices (MedTech Insight)
Regulatory Recon is our regular intelligence briefing for the regulatory affairs space, bringing you the top regulatory, biopharma and medtech news stories from around the globe. Regulatory Recon is published each week on Monday, Tuesday and Thursday.

A story’s inclusion in Regulatory Recon does not imply endorsement by Regulatory Focus or RAPS.
×

Welcome to the new RAPS Digital Experience

We have completed our migration to a new platform and are pleased to introduce the updated site.

What to expect: If you have an existing login, please RESET YOUR PASSWORD before signing in. After you log in for the first time, you will be prompted to confirm your profile preferences, which will be used to personalize content.

We encourage you to explore the new website and visit your updated My RAPS page. If you need assistance, please review our FAQ page.

We welcome your feedback. Please let us know how we can continue to improve your experience.